Lepirica Capsule 50 mg (Pregabalin)
Pregabalin 50mg
Hard capsule · Prescription medication
(Co., Ltd.) Boryung Biopharma
MFDS item code 202000753 · Approved 2020.02.10
This product's status changed to Expired on 2025.02.10. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
This medication is used for the treatment of peripheral and central neuropathic pain in adults, as an adjunctive treatment for partial seizures in epilepsy, and for the treatment of fibromyalgia.
This medicine, as pregabalin, is administered orally in two divided doses per day, with or without food. Since this medicine is mainly excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased to 150 mg twice daily (300 mg/day) within 1 week. For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased to 225 mg twice daily (450 mg/day) within 1 week. Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is mainly excreted by the kidneys unchanged. Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula: Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) 72 x serum creatinine concentration (serum creatinine, mg/dL) * For women, multiply the result obtained from the above equation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an extra supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1] Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID ≥30-<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID ≥15-<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Initial dose 25, maximum dose 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosing regimen. b: An additional dose refers to a supplemental dose administered as a single dose. 6. Patients with hepatic impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Elderly patients (65 years of age or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient data on safety and efficacy.
This medication is used as an antiepileptic agent and may increase the risk of suicidal thoughts or behaviors; patients and caregivers should monitor for these symptoms closely. It should not be used in patients with hypersensitivity to this drug or those with specific genetic lactose metabolism disorders. Diabetic patients may require adjustments in the dosage of blood sugar control medications due to weight gain. If symptoms of hypersensitivity such as angioedema occur, use should be discontinued immediately. Elderly patients may experience side effects such as dizziness, drowsiness, and confusion, so caution is needed, and they should avoid dangerous activities until they are accustomed to the effects of the medication. Visual disturbances or changes in vision may occur, and if these symptoms appear, consideration should be given to discontinuing the medication. Abruptly stopping the medication may result in withdrawal symptoms such as insomnia, headaches, and anxiety, so it should be tapered gradually according to a doctor's instructions. As there is a potential for drug abuse and dependence, patients with a history of mental illness or drug abuse should be especially cautious. Patients with impaired kidney function may require dosage adjustments. Patients with heart disease should use this medication with caution, and there is an increased risk of central nervous system depression if taken with opioid analgesics. Patients with respiratory diseases, renal impairment, or elderly patients may be at higher risk of severe respiratory depression and may need dosage adjustments. Early pregnancy poses a risk of fetal malformations, so the drug should not be administered to pregnant women, and women of childbearing age should use effective contraception. Breastfeeding women are advised to avoid breastfeeding as this drug can be passed to the infant through breast milk. Dangerous activities such as driving or operating machinery should be avoided until dizziness and drowsiness have resolved. Severe skin reactions may occur, so if any skin abnormalities appear, discontinue the drug immediately and consult healthcare professionals. In case of overdose, confusion, drowsiness, depression, and other symptoms may occur, and treatment such as dialysis may be necessary.
Suicidal ideation, suicidal behavior, depression, abnormal changes in mood and behavior, angioedema, facial edema, perioral edema, upper airway edema, dizziness, drowsiness, loss of consciousness, confusion, mental disorder, blurred vision, changes in vision, insomnia, headache, nausea, anxiety, diarrhea, influenza-like illness, restlessness, suicidal thoughts, pain, seizures, hyperhidrosis, misuse, abuse, dependence, withdrawal symptoms, rhinitis, neutropenia, increased appetite, decreased appetite, hypoglycemia, confusion, spatial disorientation, irritability, euphoria, decreased libido, depersonalization, paroxysmal dysesthesia, restlessness, mood fluctuations, emotional blunting, emotional elevation, difficulty finding appropriate terminology, hallucinations, abnormal dreams, increased libido, panic attacks, inability to suppress impulses, apathy, ataxia, motor coordination abnormalities, balance disorders, amnesia, attention deficit, memory impairment, tremor, dysarthria, sensory abnormalities, sensory deficits, sedation, somnolence, cognitive impairment, nystagmus, speech disorders, myokymia, decreased reflexes, motor abnormalities, psychomotor agitation, positional vertigo, hypersensitivity, burning sensation, action tremor, syncope, stupor, hypokinesia, olfactory disturbances, taste loss, writing difficulties, blurred vision, diplopia, indirect vision loss, visual disturbances, visual field defects, photopsia, dry eyes, eye swelling, decreased vision, ocular pain, eye strain, increased tear production, ocular irritation, mydriasis, during vibration, changes in depth perception of vision, strabismus, visual brightness, vertigo, auditory hypersensitivity, first-degree atrioventricular block, tachycardia, sinus bradycardia, sinus tachycardia, sinus arrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, shortness of breath, epistaxis, cough, nasal congestion, rhinitis, snoring, pharyngeal tension, nasal dryness, respiratory suppression, vomiting, abdominal distension, constipation, dry mouth, flatulence, excessive salivation, gastroesophageal reflux disease, decreased oral sensation, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, cold sweat, muscle cramps, arthralgia, back pain, limb pain, cervical spasms, joint swelling, myalgia, muscle spasms, neck pain, muscle rigidity, rhabdomyolysis, urination disorders, urinary incontinence, decreased urination, kidney failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, mastalgia, nipple discharge, gynecomastia, peripheral edema, edema, gait abnormalities, falling, feeling drunk, sensory abnormalities, fatigue, tightness in the chest, generalized edema, pain, fever, chills, weakness, thirst, weight gain, increased alanine aminotransferase, increased serum creatine phosphokinase, increased aspartate aminotransferase, increased blood sugar, decreased platelet count, decreased serum potassium, weight loss, increased serum creatinine, decreased white blood cell count, hypersensitivity, allergic reactions, headache, keratitis, congestive heart failure, pulmonary edema, nausea, diarrhea, tongue swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, lethargy, delirium, paralysis (facial paralysis), affective disorder, drowsiness, state of confusion, agitation, restlessness, seizures, shock, anaphylaxis-like symptoms, mucocutaneous syndrome, erythema multiforme
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air or moisture from entering. It is best stored at room temperature between 15 to 30 degrees Celsius. This will help maintain the medication's efficacy for a longer period.
Hard capsule with a dark blue upper part and white lower part containing white powder
30 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Pregabalin 50mg
Hard capsule · Prescription medication
(Co., Ltd.) Boryung Biopharma

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.